Seelos Therapeutics Inc

NASDAQ:SEEL  
1.64
-0.10 (-5.75%)
Products

Seelos Therapeutics Says FDA Accepts IND Application And Grants Fast Track Designation For Spinocerebellar Ataxia Treatment

Published: 11/08/2021 13:28 GMT
Seelos Therapeutics Inc (SEEL) - Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for Sls-005 (iv Trehalose) for the Treatment of Spinocerebellar Ataxia.
Seelos Therapeutics Inc - Global Phase Iib/iii Study for Sls-005 to Be Initiated in Early 2022.